Mylan sent a seven-page letter to U.S. Senate Judiciary Chairman Chuck Grassley in an attempt to answer his questions about EpiPen's price hikes.chairman responded by calling the letter "incomplete," according to Bloomberg.
Here are five highlights:
1. Chairman Grassley said although he does appreciate the company responding to his inquires, the letter does not fully answer his questions.
2. Mylan sent the letter on Sept. 8, which features content that Chairman Grassley says had gaps as to why Mylan instituted the significant price hikes.
3. The chairman is not the only lawmaker to implore a response from Mylan. The company may face confessionals hearings, with Democratic candidate Hillary Clinton voicing criticism of Mylan.
4. In August, EpiPen said it would offer a generic product, which carries a $300 list price. Mylan is also working with school district and patient advocacy groups. New York Attorney General Eric Schneiderman is investigating the program in which Mylan provided 700,000 free EpiPens.
5. Chairman Grassley said he plans to continue asking questions and working on legislation to bring more generic drugs into the marketplace.
More articles on quality & infection control:
Global healthcare radiofrequency identification market to hit $2.2B by 2020: 3 things to know
How much weight should parents' opinions pull in their child's treatment? 4 things to know
Electronic boards highlighting staff's hand hygiene boost health system's compliance rates: 5 key points
